Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSCSNASDAQ:PETVNASDAQ:PSTVNASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSCSHeart Test Laboratories$3.20-0.9%$3.16$2.36▼$13.50$3.46M2.71127,446 shs62,674 shsPETVPetVivo$0.54+4.7%$0.55$0.29▼$0.98$13.19M1.8521,069 shs10,701 shsPSTVPlus Therapeutics$0.79-6.5%$0.92$0.24▼$2.67$13.39M0.684.25 million shs903,849 shsVVOSVivos Therapeutics$2.63-3.0%$2.96$1.91▼$6.28$15.49M7.31453,381 shs54,134 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSCSHeart Test Laboratories0.00%-3.18%+12.24%-3.32%-67.15%PETVPetVivo0.00%-2.02%-8.33%-29.29%-33.57%PSTVPlus Therapeutics0.00%+19.63%-32.08%-35.42%-53.38%VVOSVivos Therapeutics0.00%+25.24%-15.43%-37.68%+1.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSCSHeart Test Laboratories2.2455 of 5 stars3.53.00.00.01.90.01.3PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/APSTVPlus Therapeutics2.3915 of 5 stars3.54.00.00.02.60.00.6VVOSVivos Therapeutics2.767 of 5 stars3.55.00.00.03.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSCSHeart Test Laboratories 3.00Buy$13.00306.25% UpsidePETVPetVivo 0.00N/AN/AN/APSTVPlus Therapeutics 3.00Buy$11.501,359.58% UpsideVVOSVivos Therapeutics 3.00Buy$6.10131.94% UpsideCurrent Analyst Ratings BreakdownLatest HSCS, PSTV, VVOS, and PETV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.004/15/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.204/1/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/28/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.503/18/2025HSCSHeart Test LaboratoriesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.003/17/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$9.00 ➝ $9.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSCSHeart Test Laboratories$14.70K235.32N/AN/A$11.16 per share0.29PETVPetVivo$1.05M12.61N/AN/A($0.03) per share-18.15PSTVPlus Therapeutics$4.91M2.73N/AN/A($0.30) per share-2.63VVOSVivos Therapeutics$15.03M1.03N/AN/A$0.22 per share11.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSCSHeart Test Laboratories-$6.61M-$7.48N/AN/AN/AN/A-117.76%-84.09%N/APETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)PSTVPlus Therapeutics-$13.32M-$2.50N/AN/AN/A-225.07%N/A-154.56%5/13/2025 (Estimated)VVOSVivos Therapeutics-$13.58M-$2.91N/AN/AN/A-86.19%-335.04%-93.58%5/13/2025 (Estimated)Latest HSCS, PSTV, VVOS, and PETV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025PSTVPlus Therapeutics-$0.24N/AN/AN/A$1.11 millionN/A5/13/2025Q1 2025VVOSVivos Therapeutics-$0.41N/AN/AN/A$3.63 millionN/A3/27/2025Q4 2024PSTVPlus Therapeutics-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 million3/27/2025Q4 2024VVOSVivos Therapeutics-$0.43-$0.28+$0.15-$0.28$3.89 million$3.70 million3/13/2025Q3 2025HSCSHeart Test Laboratories-$2.53-$2.5722-$0.0422-$2.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSCSHeart Test LaboratoriesN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSCSHeart Test Laboratories0.011.721.52PETVPetVivo0.020.420.47PSTVPlus TherapeuticsN/A0.440.44VVOSVivos TherapeuticsN/A1.441.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSCSHeart Test Laboratories17.24%PETVPetVivo24.55%PSTVPlus Therapeutics3.28%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipHSCSHeart Test Laboratories1.80%PETVPetVivo10.84%PSTVPlus Therapeutics5.49%VVOSVivos Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSCSHeart Test Laboratories101.08 million962,000Not OptionablePETVPetVivo2024.22 million19.06 millionNot OptionablePSTVPlus Therapeutics2017.00 million5.57 millionNot OptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableHSCS, PSTV, VVOS, and PETV HeadlinesRecent News About These CompaniesVivos to acquire sleep centerApril 17, 2025 | hmenews.comVivos Therapeutics announces agreement to acquire operating assets of SCNApril 17, 2025 | markets.businessinsider.comVivos Opens New Sleep CenterApril 16, 2025 | baystreet.caVivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in NevadaApril 16, 2025 | globenewswire.comVivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global PartnersApril 2, 2025 | markets.businessinsider.comVivos Therapeutics’ Earnings Call Highlights Growth and ExpansionApril 1, 2025 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue EstimatesMarch 31, 2025 | zacks.comVivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational UpdateMarch 31, 2025 | globenewswire.com4VVOS : Earnings Outlook For Vivos TherapeuticsMarch 28, 2025 | benzinga.comVivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference CallMarch 28, 2025 | globenewswire.comVivos Therapeutics expands strategic alliance with Rebis HealthFebruary 25, 2025 | markets.businessinsider.comVivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions NationwideFebruary 24, 2025 | markets.businessinsider.comVivos Therapeutics sees strong adoption of OSA treatment, expands strategic allianceFebruary 24, 2025 | proactiveinvestors.comVivos Therapeutics Enters Market Offering Agreement with WainwrightFebruary 14, 2025 | tipranks.comVivos Therapeutics files $50M mixed securities shelfFebruary 11, 2025 | markets.businessinsider.comVivos Therapeutics files to sell 854,332 shares of common stock for holdersJanuary 22, 2025 | markets.businessinsider.comBest Momentum Stocks to Buy for January 8thJanuary 8, 2025 | zacks.comNew Strong Buy Stocks for January 8thJanuary 8, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSCS, PSTV, VVOS, and PETV Company DescriptionsHeart Test Laboratories NASDAQ:HSCS$3.20 -0.03 (-0.93%) Closing price 04/25/2025 03:55 PM EasternExtended Trading$3.40 +0.20 (+6.25%) As of 04/25/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.PetVivo NASDAQ:PETV$0.54 +0.02 (+4.73%) As of 04/25/2025 03:59 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Plus Therapeutics NASDAQ:PSTV$0.79 -0.05 (-6.50%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.79 +0.00 (+0.14%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Vivos Therapeutics NASDAQ:VVOS$2.63 -0.08 (-2.95%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.66 +0.03 (+1.10%) As of 04/25/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
